Chinook affinity study
WebApr 7, 2024 · Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2024. About Chinook Therapeutics, Inc.Chinook Therapeutics, Inc. is a clinical-stage biotechnology ... WebThe AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and …
Chinook affinity study
Did you know?
Webongoing AFFINITY study demonstrate atrasentan is generally well-tolerated and results in a mean 54.7% reduction in proteinuria at Week 24 (N=19; ASN 2024, TH-PO497) The … WebSep 28, 2024 · The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Cohorts will consist of patients with: IgA nephropathy (IgAN) with urine protein:creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g
WebApr 11, 2024 · Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective ... WebMay 12, 2024 · Chinook plans to present data from the IgAN patient cohort of the phase 2 AFFINITY trial in an oral presentation at the 59 th ERA Congress on May 20, 2024, and provide a program update on ...
WebApr 7, 2024 · Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2024. SEATTLE, April 07, 2024 (GLOBE NEWSWIRE) -- Chinook … WebThe AFFINITY study, Chinook’s phase 2 open-label basket trial of atrasentan in additional proteinuric glomerular diseases, is currently enrolling patients. Four initial cohorts will consist of patients with: IgAN …
WebThe AFFINITY study is a phase 2 clinical trial testing an investigational medication called atrasentan. Atrasentan has potential to benefit in Alport Syndrome and other glomerular diseases by reducing the amount of …
WebJun 19, 2024 · The AFFINITY Study (see www.clinicaltrials.gov, identifier NCT04573920) is an ongoing global phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. The four AFFINITY cohorts consist of patients with: biopsy-proven ... greenhouse consultancyWebMay 20, 2024 · The AFFINITY Study (see www.clinicaltrials.gov, identifier NCT04573920) is an ongoing global phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. The four AFFINITY cohorts consist of patients with: biopsy-proven ... fly away home song from movieWebOct 14, 2024 · Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the preclinical efficacy profile of CHK-336 and multiple abstracts detailing Chinook's multidimensional approach to precision medicine in nephrology fly away home songsWebkidney failure in a study of over 5,300 patients with diabetic kidney disease (DKD), representsa promising therapy to reduce proteinuria and preserve kidney function in proteinuric glomerular diseases. Objective: Global, phase 2, open-label basket study to study the efficacyand safety of atrasentanin patients with proteinuric glomerular diseases. greenhouse contractor philadelphiaWebDec 14, 2024 · Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2024, with data from one or more additional cohorts expected in the second half of 2024 flyaway homes shipping containersWeb• In a Phase 2 study in DKD (RADAR), atrasentan reduced urine albumin-creatinine ratios by an average of 35% (95% confidence interval [CI]: 24, 45; P =0.001). 3 • In a global Phase 3 outcome study in DKD (SONAR), the atrasentan treatment group demonstrated a 35% reduced risk of the primary composite outcome of doubling serum creatinine or fly away home soundtrack songsWebApr 11, 2024 · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision ... flyaway homes los angeles